在-葡萄糖共同输送器1/2抑制剂的近期进展和前景
Cahit Demirkiran1, Seniz Demiryurek2, Abdullah Tuncay Demiryurek1
1Department of Medical Pharmacology, Faculty of Medicine, Gaziantep University, Gaziantep, 27310, Turkiye.
Mini reviews in medicinal chemistry
|August 20, 2024
概括
-葡萄糖共运输体-1/2 (SGLT1/2) 抑制剂是治疗2型糖尿病的降血糖药物. 除了血糖控制之外,这些glifozins提供了显著的心脏和脏保护益处,扩大了它们的治疗潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- -葡萄糖辅运输体-1/2 (SGLT1/2) 抑制剂主要用于2型糖尿病 (T2D).
- 这些glifozin减少葡萄糖在脏中的再吸收.
- 新出现的证据表明,除了血糖控制之外,还有好处,包括对心力衰竭 (HF) 和慢性病.
研究的目的:
- 审查SGLT1/2抑制剂的既定和新兴治疗作用.
- 为了突出其心血管和脏的保护作用.
- 探索在其他疾病中的潜在应用.
主要方法:
- 对SGLT1/2抑制剂的临床试验和研究研究的综述.
- 对药理机制和临床结果的分析.
- 综合当前的建议和未来的研究方向.
主要成果:
- SGLT2 抑制剂对于管理心力衰竭与减少喷射分数 (HFrEF) 的基础,并在心力衰竭与保存喷射分数 (HFpEF) 中有益.
- 这些药物显示出显著的心脏和脏保护性质.
- 全球已批准11种SGLT1/2抑制剂,目前正在研究它们用于代谢,瘤,血液和神经疾病的使用.
结论:
- SGLT1/2 抑制剂为T2D管理和心血管保护提供了巨大的好处.
- 它们的心脏和脏保护作用已被证实,导致它们在HF治疗中使用.
- 需要进一步的研究,以充分阐明SGLT1/2抑制剂在更广泛疾病中的潜力.
相关概念视频
Glucose Transporters
22.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Secondary Active Transport
118.7K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.7K
Glucose Absorption Into the Small Intestine
31.5K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
Oral Hypoglycemic Agents: Glinides
149
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
149


